Sinovac Vaccine up to 97% Effective in Early Trial, Indonesia Partner Says


Follow Bloomberg on LINE messenger for all the business news and analysis you need.

Chinese vaccine maker Sinovac Biotech Ltd.’s coronavirus shot created antibodies among 97% of those administered with it in a final stage trial in Indonesia, said a company spokesperson on Tuesday.

Known as the seroconversion rate, this is separate from the vaccine’s efficacy, as a high seroconversion rate does not necessarily mean that the vaccine effectively protects people against Covid-19. Sinovac is still in the midst of determining its shot’s efficacy from final stage trial data, said the spokesperson.

Earlier, Iwan Setiawan, head of corporate communications at Indonesia’s state-owned company PT Bio Farma, told reporters that Sinovac’s shot had proven 97% effective in early trials there.

©2020 Bloomberg L.P.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.